QbD Driven Approach to Early Stage Drug Delivery Innovation with the Hydralese® Polymer Platform

Session details:

• Secant Group’s patented Hydralese® polymer platform combines tunable PGEU chemistry with a Quality by Design-driven framework for long-acting implant (LAI) drug delivery across a range of APIs and therapeutic applications.
• A Phase 0 Quality by Design-based development approach supports reproducible, predictable performance and systematic optimization of formulation, degradation, and drug-release characteristics.
• Integrated technical, analytical, and digital capabilities enable collaborative development to address complex formulation challenges and advance controlled-release drug delivery.